Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Capsida Biotherapeutics Inc.

https://capsida.com/

Latest From Capsida Biotherapeutics Inc.

AstraZeneca’s LogicBio Buyout Will Give Other Troubled Gene Therapy Companies Hope

Many gene therapies companies have faced R&D and financial problems this year but the longer term potential of the field and low prices might tempt big pharma into deals.

Gene Therapy FDA

Deal Watch: Roche Terminates Gene Therapy Alliance, Partners In IBD With Synlogic

Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.

Deal Watch Business Strategies

Finance Watch: Dyno Therapeutics Raises $100m For Novel AAV Vectors

Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round. 

Finance Watch Financing
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
UsernamePublicRestriction

Register